Skip to main content
Premium Trial:

Request an Annual Quote

XDx's AlloMap and NimbleGen's Microbial Whole-Genome Resequencing Technology

Premium

XDx last week launched AlloMap, a molecular expression profiling test capable of predicting patient outcomes following heart transplantation, the company said in a statement. The test "has a high negative predictive value" for heart transplant rejection, guiding treatment with anti-rejection drugs and reducing problem biopsies, XDx said.


NimbleGen this week introduced its Microbial Whole-Genome Resequencing Technology, which "surveys an entire microbial genome to pinpoint genetic changes" to the SNP level, the company said in a statement.

Filed under